Predictive Model of Early Spontaneous Ductus Arteriosus Closure Based on Neonatologist Performed Echocardiography in Preterm Infants

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2021 Mar 15

PMID 33718310

Citations 1

Authors

Maria Carmen Bravo

Rebeca Sanchez

Ana Isabel Blanco

Itsaso Losantos

Adelina Pellicer

Affiliations

Soon will be listed here.

Abstract

Patent ductus arteriosus (PDA) treatment remains controversial. Modeling on the predictive capacity of early spontaneous PDA closure would help in decision-making. To design a predictive model of early spontaneous PDA closure. As part of a trial to assess efficacy and safety of two ibuprofen treatment schemes for PDA, infants below 29 weeks' gestation were scanned between 18 and 72 h of birth, and serially if indicated. PDA treatment was decided based on echocardiography signs of lung overflow or systemic hypoperfusion and clinical criteria. A PDA score that included the echocardiographic parameters significantly associated with treatment prescription was retrospectively applied. Perinatal variables and screening score were included in a backwards elimination model to predict early spontaneous closure. Among 87 eligible infants (27 weeks' gestation; age at screening 45 h), 21 received ibuprofen at 69 h of life [screening score = 7 (IQR = 5-8.5); score at treatment = 9 (IQR = 8-9)], while 42 infants had conservative management, [screening score = 1 (IQR = 0-4)]. Twenty four infants were excluded (ibuprofen contraindication, declined consent or incomplete echocardiography). Screening score showed an AUC = 0.93 to predict early spontaneous PDA closure, [cut-off value = 4.5 (sensitivity = 0.90, specificity = 0.86)]. The predictive model for early spontaneous PDA closure followed the equation: Log (p/1-p) = -28.41 + 1.23 gestational age -0.87 PDA screening score. A predictive model of early spontaneous PDA closure that includes gestational age and the screening PDA score is proposed to help clinicians in the decision- making for PDA treatment. In addition, this model could be used in future intervention trials aimed to prevent PDA related morbidities to improve the eligibility criteria.

Citing Articles

Randomized Trial on Echocardiography-Guided Ductus Arteriosus Treatment to Reduce Necrotizing Enterocolitis.

Carmen Bravo M, Sanchez-Salmador R, Moral-Pumarega M, Lopez-Azorin M, Mosqueda-Pena R, Dorronsoro I Front Pediatr. 2022; 9:807712.

PMID: 35155319 PMC: 8833153. DOI: 10.3389/fped.2021.807712.

References

Harkin P, Marttila R, Pokka T, Saarela T, Hallman M . Morbidities associated with patent ductus arteriosus in preterm infants. Nationwide cohort study. J Matern Fetal Neonatal Med. 2017; 31(19):2576-2583. DOI: 10.1080/14767058.2017.1347921. View

McNamara P, Sehgal A . Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007; 92(6):F424-7. PMC: 2675381. DOI: 10.1136/adc.2007.118117. View

Kluckow M, Jeffery M, Gill A, Evans N . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2013; 99(2):F99-F104. DOI: 10.1136/archdischild-2013-304695. View

Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I . Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009; 123(1):e138-44. DOI: 10.1542/peds.2008-2418. View

Flint R, Ter Heine R, Spaans E, Burger D, de Klerk J, Allegaert K . Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. Eur J Clin Pharmacol. 2018; 74(12):1585-1591. PMC: 6244763. DOI: 10.1007/s00228-018-2529-y. View

Dani C, Poggi C, Fontanelli G . Relationship between platelet count and volume and spontaneous and pharmacological closure of ductus arteriosus in preterm infants. Am J Perinatol. 2012; 30(5):359-64. DOI: 10.1055/s-0032-1324702. View

Benitz W . Learning to live with patency of the ductus arteriosus in preterm infants. J Perinatol. 2011; 31 Suppl 1:S42-8. DOI: 10.1038/jp.2010.175. View

Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts R, Saigal S . Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001; 344(26):1966-72. DOI: 10.1056/NEJM200106283442602. View

Weber S, Weiss K, Buhrer C, Hansmann G, Koehne P, Sallmon H . Natural History of Patent Ductus Arteriosus in Very Low Birth Weight Infants after Discharge. J Pediatr. 2015; 167(5):1149-51. DOI: 10.1016/j.jpeds.2015.06.032. View

10.

Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld C . Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006; 117(4):1113-21. DOI: 10.1542/peds.2005-1528. View

11.

Clyman R, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Hakansson S . PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. J Pediatr. 2018; 205:41-48.e6. PMC: 6502709. DOI: 10.1016/j.jpeds.2018.09.012. View

12.

Sehgal A, Paul E, Menahem S . Functional echocardiography in staging for ductal disease severity : role in predicting outcomes. Eur J Pediatr. 2012; 172(2):179-84. DOI: 10.1007/s00431-012-1851-0. View

13.

Aranda J, Clyman R, Cox B, van Overmeire B, Wozniak P, Sosenko I . A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. Am J Perinatol. 2008; 26(3):235-45. DOI: 10.1055/s-0028-1103515. View

14.

Rolland A, Shankar-Aguilera S, Diomande D, Zupan-Simunek V, Boileau P . Natural evolution of patent ductus arteriosus in the extremely preterm infant. Arch Dis Child Fetal Neonatal Ed. 2014; 100(1):F55-8. DOI: 10.1136/archdischild-2014-306339. View

15.

Schena F, Francescato G, Cappelleri A, Picciolli I, Mayer A, Mosca F . Association between Hemodynamically Significant Patent Ductus Arteriosus and Bronchopulmonary Dysplasia. J Pediatr. 2015; 166(6):1488-92. DOI: 10.1016/j.jpeds.2015.03.012. View

16.

Mosalli R, AlFaleh K . Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. Cochrane Database Syst Rev. 2008; (1):CD006181. PMC: 8916218. DOI: 10.1002/14651858.CD006181.pub2. View

17.

El-Khuffash A, James A, Corcoran J, Dicker P, Franklin O, Elsayed Y . A Patent Ductus Arteriosus Severity Score Predicts Chronic Lung Disease or Death before Discharge. J Pediatr. 2015; 167(6):1354-1361.e2. DOI: 10.1016/j.jpeds.2015.09.028. View

18.

Osborn D, Evans N, Kluckow M . Hemodynamic and antecedent risk factors of early and late periventricular/intraventricular hemorrhage in premature infants. Pediatrics. 2003; 112(1 Pt 1):33-9. DOI: 10.1542/peds.112.1.33. View

19.

Fowlie P, Davis P, McGuire W . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010; (7):CD000174. PMC: 7045285. DOI: 10.1002/14651858.CD000174.pub2. View

20.

Clyman R . The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol. 2013; 37(2):102-7. PMC: 3627220. DOI: 10.1053/j.semperi.2013.01.006. View